Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes

Cancer Control

Volumn 13, Issue SUPPL., 2006, Pages 12-16

  List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACETYLSALICYLIC ACID; AZACITIDINE; GROWTH FACTOR; LENALIDOMIDE; MYELOID GROWTH FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; BONE MARROW SUPPRESSION; CHROMOSOME 5Q; CHROMOSOME DELETION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENTIATION; ERYTHROCYTE TRANSFUSION; HUMAN; IRON CHELATION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PHLEBOTOMY; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 33846424922     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601304s03     Document Type: Review

References (22)

1. Oliva EN, Dimitrov BD, Benedetto F, et al. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndromes. Leuk Res. 2005;29:1217-1219.
2. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594-7603.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89: 2079-2088.
4. Gore S. Classification, treatment goals, and management principles for myelodysplastic syndromes. Cancer Control. 2004;11(suppl):3-6.
5. List A, Vardiman J, Issa JP, et al. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004:297-317.
6. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology v4.2006. Myelodysplastic syndromes. 2006 National Comprehensive Cancer Network. Available at: http://www.nccn.org. Accessed November 21, 2006.
7. List AF, Sandberg AA, Doll DC. Myelodysplastic syndromes. In: Wintrobe's Clinical Hematology. 11th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004:2207-2234.
8. Yilmaz Z, Sahin FI, Kizilkilic E, et al. Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients. Clin Exp Med. 2005;5:55-59.
9. Panani AD, Roussos C. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications. Cancer Lett. 2006;235: 177-190.
10. Giagounidis AA, Germing U, Strupp C, et al. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol. 2005;82:569-571.
11. Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood. 2002;99:4638-4641.
12. Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res. 2006;12:5-10.
13. Giagounidis AA, Germing U, Wainscoat JS, et al. The 5q- syndrome. Hematology. 2004;9:271-277.
14. Giagounidis AA, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia. 2004;18:113-119.
15. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671-3674.
16. List A, Kurtin S, Roe DJ. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549-557.
17. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355: 1456-1465.
18. List AF, Dewald G, Bennett J, et al. Results of the MDS-002 and -003 international phase II studies evaluating lenalidomide (CC-5013; Revlimid®) in the treatment of transfusion-dependent patients with myelodysplastic syndrome (MDS). Haematologica. 2005;90(suppl 2):307a.
19. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. 1997;99:344-351.
20. Howe RB, Porwit-MacDonald A, Wanat R, et al. The WHO classification of MDS does make a difference. Blood. 2004;103:3265-3270.
21. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102:3025-3027.
22. Sloand EM, Greenberg P, Wu C, et al. Immunosuppressive treatment is associated with durable responses and a survival advantage in younger patients with Int-1 myelodysplastic syndrome. Blood. 2005;106:707a.